Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Next Previous
Trial Profile

A Phase I Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 322 (Primary)
  • Indications Haematological malignancies; Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innovent Biologics

Most Recent Events

  • 06 Nov 2024 Status changed from recruiting to completed.
  • 15 Jun 2023 Results (n=24) assessing the safety, tolerability and efficacy of IBI322 monotherapy in anti-PD-1or PD-L1 treatment-resistant cHL pts presented at the 28th Congress of the European Haematology Association
  • 12 Jun 2023 According to Innovent Biologics media release, dose-expansion cohort results of this study was presented at the 28th Annual Meeting of the European Society of Hematology (EHA 2023) held in Frankfurt, Germany, from June 8 to 15, 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top